NCT03405441 - A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

September 4, 2018

Study Completion Date

September 4, 2018

Conditions

Healthy

Interventions

DRUG

JNJ-55375515 Dose Level 1

Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.

DRUG

JNJ-55375515 Dose Level 2

Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.

DRUG

JNJ-55375515 Dose Level 3

Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.

DRUG

JNJ-55375515 Dose Level 4

Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.

DRUG

JNJ-55375515 Dose Level 5

Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.

DRUG

JNJ-55375515 Dose Level 6

Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.

DRUG

Placebo

All participants will receive matching placebo orally in Part 1 and Part 2 of the study.

DRUG

JNJ-55375515

Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.

Trial Locations (1)

PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini, Groningen

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY